An investor inquired on the investor interaction platform: "The company's centralized procurement bid wins increased significantly in the third quarter. Why didn't the company issue corresponding announcements to enhance investor confidence?" Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693.SZ) responded on September 25th via the investor interaction platform, stating that all of the company's centralized procurement projects this year are renewals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments